FDA approves less frequent dosing for BMS's Opdivo

FDA approved an sBLA for Opdivo nivolumab from Bristol-Myers Squibb Co. (NYSE:BMY) to include dosing every four weeks for most of the anti-PD-1 mAb’s approved indications and a

Read the full 288 word article

User Sign In